Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Date:6/8/2008

are deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products. For additional information, please visit http://www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential f
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... and CHESTERBROOK, Pa. , Sept. 18, ... VVUS ) and Auxilium Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved a supplemental new drug application ... only FDA-approved erectile dysfunction (ED) medication indicated to be taken ... STENDRA is a prescription medication in a class of ...
(Date:9/17/2014)... , Sept. 17, 2014 BRIC Gynecological ... GlobalData,s new report, "BRIC Gynecological ... data on the BRIC Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... MONICA, Calif. , Sept. 17, 2014  Dr. ... is at the White House today for National Recovery ... 46 that consumer advocates released today. Consumer advocates were ... woman who spoke out after losing her fiancée ... discovering that the doctor had a history of crack ...
Breaking Medicine Technology:VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3
... 18, 2011 Adeona Pharmaceuticals, Inc. (Amex: ... central nervous system diseases, announced today that it will ... 8, 2011 from 3:00-5:00 P.M. (EST) at the Kensington ... Arbor, Adeona,s management team welcomes shareholders, potential investors and ...
... Companion Animal Health has launched its second product in ... + milbemycin oxime), a broad-spectrum parasiticide that kills fleas ... flea infestations, the prevention of heartworm disease and the ... infections in dogs and puppies 8 weeks and older, ...
Cached Medicine Technology:Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease 2Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease 3Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
(Date:9/18/2014)... 2014 With the development of ... of adjusting human body physiology, preventing diseases, promoting ... with a variety of specific populations. In 2013, ... reached RMB187.4 billion, up 12.0% year on year, ... View Full Report at http://www.marketresearchreports.biz/analysis/223449 , ...
(Date:9/18/2014)... MA (PRWEB) September 18, 2014 ... its team and surgeon partners in Less Exposure ... joining SpineFrontier, Tamara authored an extensive education curriculum ... a Masters in Science in Organizational Leadership, and ... industries for eleven years. Bringing her to the ...
(Date:9/18/2014)... Dr. Suzaunna Clark, Psychologist, Life Coach ... beauty has to be seen to be believed and ... order to be used. Together, both lead to hearts ... how to do both. , Dr. Clark ... Healing Hearts system, which provides professional guidance on dealing ...
(Date:9/18/2014)... Specialty Teleradiology LLC, a provider of teleradiology services ... achieved Meaningful Use and increased operational efficiency since ... developed by RamSoft. , Before implementing PowerServer ... PACS and a RIS that was built in-house. ... oncology to other subspecialties, they needed a robust, ...
(Date:9/18/2014)... 2014 N-Zyme Scientifics LLC achieved a ... first product a mere 8 months after company startup. ... performance glycan release enzyme used in the “Biologics” industry ... basis for tissue pathology on Mass Spec devices. PRIME™ ... the North American market (PNGase F PRIMETM). N-Zyme ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:N-Zyme Scientifics Announces Successful Product Launch 2
... latest research unhealthy ways of expressing anger are associated ... //expressing anger." According to past research, stress can also ... not practice healthy anger or stress management may be ... adolescents, ages 14 to 17, for three years. In ...
... New research shows one virus could help fight another. ... // hepatitis G , may hold a key ... ,Researchers analyzed results from the Multicenter Acquired ... large group of HIV-infected men in the United States ...
... put a woman at increased risk of developing asthma, report ... obstructive pulmonary disease (COPD) risk. ,The incidence of both ... 5 percent to 8 percent of Americans have asthma, and ... since 1982. Since the prevalence of asthma tends to change ...
... lose significant bone mass in the first year after the ... their bodies from rejecting the new organ. The bone loss ... of fractures among this group ranges from 22 percent to ... treatment, but which drugs work best in this situation is ...
... is showing promising results.For the past decade, researchers // ... immunotoxin is bioengineered and consists of only the most ... commonly used to fight leukemia. One of those immunotoxins, ... study. ,Researchers say in a phase I study, ...
... estimates that 40 million people are infected with the ... In some African countries, 40 percent of pregnant women ... caught HIV. ,In impoverished areas where the ... one-time treatment for HIV-infected pregnant women to keep them ...
Cached Medicine News:Health News:Drug to stop HIV spread to babies may Indirectly harm The Mother 2
... Alliance Catheter Delivery System (CDS) ... stabilization of the Aescula LV ... has a patented coronary sinus ... and easy access to the ...
... PCS2 system is Haemonetics ... collection of plasma and ... the collection of "jumbo" ... platelet-poor plasma with optional ...
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... Pipette* provides quick, convenient, repetitive dispensing ... Combitips have a polyethylene plunger and ... for use with most reagents. ... Five separate volumes can be selected ...
Medicine Products: